

Over 2 million prescriptions in the U.S. result in an adverse reaction because response rates vary. Pharmacogenomic risk assessments and testing can help communities understand how a resident's body metabolizes a drug compound so that the care team can customize treatment and calculate optimal dosing.



Precision Medicine for Optimal Outcomes

Pharmacogenomics (PGx) is the study of drug-genome interactions and their clinical implications. This form of precision medicine looks for genetic markers that indicate how a resident might respond to a drug.

Some Key Conditions PGx Targets:

- Cardiology
- Diabetes
- Gastroenterology
- Oncology
- Organ transplantation
- Urology
- And more ...

No Community Cost, Seamless Resident Billing

There's no cost to communities to offer the risk assessments and testing and AccessDx manages billing to residents' insurance directly.

1 Simple Test, 450+ Medications

Because of differences in the way a resident's body metabolize a specific drug compound, they may experience improper dosing, side effects, and drug-drug interactions that can be potentially dangerous.

Today, there are more than 450 medications whose use is improved by understanding a resident's genetic makeup based on FDA drug labels. Moreover, the Clinical Pharmacogenetic Implementation Consortium publishes dosing guidelines for clinicians when genotype data is available.

A simple DNA test – taken with a cheek swab – can reveal how a resident's body metabolizes a specific drug compound to inform the care team so it can customize treatment and calculate optimal dosing. The results can assist communities in identifying, monitoring, and managing potential issues associated with resident medications.

3 Benefits for Communities and Residents:

1. Fewer adverse events
2. Increased cost savings
3. Better outcomes

Contact Us to Learn More:
PharMerica@AccessDxLab.com

